நோவர்த்திச் பிரிவு தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோவர்த்திச் பிரிவு தகவல்தொடர்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோவர்த்திச் பிரிவு தகவல்தொடர்புகள் Today - Breaking & Trending Today

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

NOVARTIS AG CHF0.50(REGD)
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase
1
In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and retinal vascular occlusion versus aflibercept ....

United States , United Kingdom , Isabella Zinck , Rachel Fink , Lookeren Campagne , Thomas Hungerbuehler , Amy Wolf , Samir Shah , Julie Masow , Beovu Basel , Sloan Simpson , John Tsai , Novartis Division Communications , World Health Organization , Global Head Of Drug Development , Novartis External Communications , Health Qual Life Outcomes , Exchange Commission , Canadian Drug Expert Committee Recommendation , National Eye Institute , National Health Insurance Pricing , European Society Of Retina Specialists , Canadian Agency For Drugs , Technologies In Health , Lancet Glob Health , Global Head ,

Novartis Pharma AG: Novartis reports one year results of Phase III MERLIN study evaluating Beovu every four week dosing and provides update on Beovu clinical program

Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept ....

United States , United Kingdom , Isabella Zinck , Rachel Fink , Lookeren Campagne , Thomas Hungerbuehler , Amy Wolf , Samir Shah , Julie Masow , Beovu Basel , Sloan Simpson , John Tsai , Novartis Division Communications , World Health Organization , Global Head Of Drug Development , Novartis External Communications , Health Qual Life Outcomes , Exchange Commission , Canadian Drug Expert Committee Recommendation , National Eye Institute , National Health Insurance Pricing , European Society Of Retina Specialists , Canadian Agency For Drugs , Technologies In Health , Lancet Glob Health , Global Head ,

Novartis Pharma AG: Novartis Phase III Beovu data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

Novartis Pharma AG: Novartis Phase III Beovu data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
1
More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease activity in DME
1
1
Phase III KESTREL and KITE trials are the first pivotal trials to assess an anti-VEGF on six-week dosing intervals in the loading phase, suggesting Beovu may offer fewer injections from the start of treatment
1
Novartis is committed to bringing Beovu 6 mg to DME patients and will submit data from KESTREL and KITE to global health authorities in H1 2021 ....

United Kingdom , United States , Isabella Zinck , Eylea Tarrytown , Thomas Hungerbuehler , Davidm Brown , Amy Wolf , Samir Shah , Jill Hopkins , Julie Masow , Beovu Basel , Sloan Simpson , Novartis Division Communications , Novartis External Communications , National Eye Institute , National Health Insurance Pricing , Novartis Pharmaceuticals , Global Development Unit Head , Clinical Research , Technologies In Health , Kite Pharma Inc , Regeneron Pharmaceuticals Inc , Canadian Drug Expert Committee Recommendation , Exchange Commission , Canadian Agency For Drugs , Association For Research ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

NOVARTIS AG CHF0.50(REGD)
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic macular edema (DME) patients
1
More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease activity in DME ....

United Kingdom , United States , Isabella Zinck , Eylea Tarrytown , Thomas Hungerbuehler , Davidm Brown , Amy Wolf , Samir Shah , Jill Hopkins , Julie Masow , Beovu Basel , Sloan Simpson , Novartis Division Communications , Novartis External Communications , National Eye Institute , National Health Insurance Pricing , Novartis Pharmaceuticals , Global Development Unit Head , Clinical Research , Technologies In Health , Kite Pharma Inc , Regeneron Pharmaceuticals Inc , Canadian Drug Expert Committee Recommendation , Exchange Commission , Canadian Agency For Drugs , Association For Research ,

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema
,
Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)
1
In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase
1
Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed
1
1
Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE ....

United States , Eric Althoff , Isabella Zinck , Dirk Sauer , Thomas Hungerbuehler , Amy Wolf , Indianj Ophthalmol , Samir Shah , Beovu Basel , Sloan Simpson , Kite Pharma Inc , Novartis Division Communications , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Canadian Drug Expert Committee Recommendation , Global Head Development , National Eye Institute , National Health Insurance Pricing , Canadian Agency For Drugs , Technologies In Health , Association For Research , Novartis Pharma , Kite Pharma , Patients With Visual Impairment Due , Diabetic Macular Edema ,